|

Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)

RECRUITINGN/ASponsored by Barts & The London NHS Trust
Actively Recruiting
PhaseN/A
SponsorBarts & The London NHS Trust
Started2024-07-26
Est. completion2027-07-26
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06096246

Summary

The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.

Eligibility

Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* Ability to give informed consent
* Age 18-85 years
* Persistent AF (atrial fibrillation lasting \> 7days) of total continuous duration \<2 years as documented in medical notes.
* Patients being considered for cardioversion.

Exclusion Criteria:

* Creatinine clearance (eGFR) \< 30mls/min
* Contraindication or unable to take anticoagulation
* Uncontrolled hypertension
* Contraindication for catheter ablation
* BMI \> 40
* Patients in Persistent AF who have had more than one previous cardioversion.
* Established diagnosis of Hypertrophic cardiomyopathy

Conditions4

Cardiac ArrhythmiaCatheter AblationHeart DiseasePersistent Atrial Fibrillation

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.